SCYNEXIS, Inc.
Moat Score — SCYNEXIS, Inc.
Total Moat Score
10 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 4 / 5 | SCYNEXIS holds the IP behind ibrexafungerp, the first FDA-approved representative of an entirely new antifungal class (the 'fungerps'), a genuine scientific breakthrough in a field dominated by decades-old azole chemistry. That mechanistic novelty was valuable enough that GSK paid to license it globally and SCYNEXIS continues to patent follow-on compounds like SCY-247. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 1 / 5 | SCYNEXIS has no cost advantage; it competes against cheap generic fluconazole and other off-patent azoles that remain the default standard of care for vulvovaginal candidiasis, and its own branded product is priced at a premium, not a discount. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 2 / 5 | Pricing power is limited and now mostly GSK's to exercise, since SCYNEXIS transferred the BREXAFEMME NDA and global commercialization rights to GSK in 2023; SCYNEXIS's own economics come from negotiated milestones and royalty rates set in the license agreement rather than from setting end-market prices itself. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | There is no network effect in antifungal pharmaceuticals; prescribing decisions are made independently by physicians per patient and the value of the drug does not increase as more patients or providers use it. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 1 / 5 | Patients and prescribers face minimal switching costs between antifungal therapies; fluconazole and other generics remain readily substitutable first-line options, and BREXAFEMME must continually win share on efficacy against resistant strains rather than relying on lock-in. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 2 / 5 | The market for novel antifungals is a real but narrow niche defined by the subset of VVC and invasive candidiasis cases resistant to or inadequately served by generic azoles; it is defensible but not large enough to deter well-funded entrants like Mycovia (Vivjoa) or pipeline competitors such as Basilea's fosmanogepix. |